🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations Dr Westin and all DUO-E investigator!! Provocative data regarding combination durva + olaparib in patients with endometrial cancer - role of biomarkers??to direct combination vs IO only maintenance therapy. Impressive PFS!

What’s Happening at ESMO!!It was my honor and pleasure to sit down with Dr. Shannon Westin and talk about DUO- E. Check out this video from your friendly SGO reporter SGO The GOG Foundation Inc. #ESMO23

avelumab + MTX was suggested as the new standard regimen for low risk GTD. Exciting >95% durable cure rate in stage 1-3, WHO score 1-6. ESMO - Eur. Oncology SGO #esmo2024

ATHENA- combo is negative. The addition of nivolumab to rucaparib was not better than rucaparib maintenance alone. The combo was more toxic. SGO ESMO - Eur. Oncology

A18 show OS benefit for addition of pembrolizumab to chemort in cervical cancer. HR 0.67. SGO ESMO - Eur. Oncology #ESMO2024

FIH SHR A1921 ADC targets tropical 2. Dose optimization in ovarian cancer 3mg/kg and 2mg/kg cohorts. Exciting response rate and PFS- 7.9 months 3mg/kg and 6.9 mg/kg for the 2mg/kg. Stomatitis common. SGO ESMO - Eur. Oncology #ESMO2024

The SGO released a clinical practice advisory addressing the nationwide shortage of intravenous (IV) solutions. These guidelines outline strategy considerations to manage the shortage in various settings while maintaining high-quality patient care. shorturl.at/q75yR

🎉A clear win at #IGCS2024!! Cadonilimab added to chemotherapy yielded improved improved progression free and overall in recurrent #cervicalcancer #gyncsm

KN-B21 subgroup analysis of dMMR cohort - highly anticipated! #IGCS2024 SGO The GOG Foundation Inc.

KN-B21 dMMR cohort highly positive 👍🤩🥰#IGCS2024 SGO The GOG Foundation Inc.

Congratulations Shannon on updated results on DUO-E at #igcs2024

Dr Westin present post hoc DUO-E exploratory analysis of biomarkers- high degree of heterogeneity with significant overlap. #IGCS2024 SGO The GOG Foundation Inc.

Wow Drop the mic moment Dr Ramez!!!! Review of DUO-E and KN-B21

Dr Eskander - Beware of Harkening #IGCS2024 SGO The GOG Foundation Inc. Important to interpret post hoc analyses with caution

Dr Noelle Cloven - reassuring QoL data for patients on RUBY trial - the trifecta- improved PFS, OS, and QoL. #IGCS2024 SGO The GOG Foundation Inc.

#IGCS 2024 Thoughtful, excellent distillation by Dr Ramez Eskander on role of IO in endometrial cancer including the unknown, encourages care in interpreting data SGO UMass Chan Medical School

Dr Jubilee Brown presents BOUQUET data at #IGCS2024 SGO The GOG Foundation Inc. Rare tumors are important to study and yes - clinical trials are feasible. Love the biomarker data ❤️

Exciting poster presentations - video with Dr Brown capturing her thoughts on the BOUQUET trial 💐❤️💐

During the #SGOMtg, Linda Duska, MD (Linda Duska) from UVA Medicine shares encouraging insights into the overall survival and progression-free survival results from the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study based on the second interim analysis. #MoffittSGO25 #SGO2025 #SGOAM2025

Our first interview of the day was with Linda Duska of UVA Medicine, who shared key OS and PFS2 data from the second interim analysis of the KEYNOTE-A18 study. Hear a brief preview of her research below, and check out onclive.com for more details! SGO #SGOMtg #gynsm